title: Nucleostemin and TWIST as predictive markers for recurrence after neoadjuvant chemotherapy for esophageal carcinoma.
abstract: We recently demonstrated that overexpression of the nucleolar GTP-binding protein nucleostemin drives the fraction of genetically-defined tumor cells that exhibit markers and tumorigenic properties of tumor initiating cells. More specifically, cells that constitutively express elevated levels of nucleostemin exhibit increased TWIST expression; expression of genes that induced pluripotent stem cells; enhanced radioresistance; tumor formation, even when small numbers of cells are implanted; and an increased propensity to metastasize. An immunohistochemical analysis of cancer stem cell markers, such as nucleostemin and TWIST has not been conducted in surgically-resected esophageal squamous cell carcinomas after neoadjuvant chemotherapy. In the present study, we examined the expression of CD133, CD44, nucleostemin, guanine nucleotide-binding protein-like 3-like, and TWIST by immunohistochemistry in a series of 54 surgically-resected specimens of esophageal squamous cell carcinomas after neoadjuvant chemotherapy. We identified that high nucleostemin proportion, TWIST intensity, and advanced pathological N stage were significantly correlated with poor relapse-free survival. Together, these observations imply nucleostemin and TWIST as the predictive markers for postoperative recurrence.
authors: Division of Gastrointestinal Oncology, National Cancer Center Hospital, Tokyo, Japan.
authors: Takako E
authors: TE
authors: Nakajima
authors: Hiroshi
authors: H
authors: Yoshida
authors: Naoko
authors: N
authors: Okamoto
authors: Kengo
authors: K
authors: Nagashima
authors: Hirokazu
authors: H
authors: Taniguchi
authors: Yasuhide
authors: Y
authors: Yamada
authors: Tadakazu
authors: T
authors: Shimoda
authors: Kenkichi
authors: K
authors: Masutomi
mesh_terms: D000071916:AC133 Antigen; D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000378:metabolism; D000970:Antineoplastic Agents / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D045744:Cell Line, Tumor; D002945:Cisplatin / Q000627:therapeutic use; D058750:Epithelial-Mesenchymal Transition; D004938:Esophageal Neoplasms / Q000188:drug therapy / Q000473:pathology* / Q000601:surgery; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use; D019204:GTP-Binding Proteins / Q000096:biosynthesis / Q000235:genetics / Q000378:metabolism*; D015972:Gene Expression Regulation, Neoplastic; D006023:Glycoproteins / Q000378:metabolism; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy; D009364:Neoplasm Recurrence, Local; D014411:Neoplastic Stem Cells; D009687:Nuclear Proteins / Q000235:genetics / Q000378:metabolism*; D010455:Peptides / Q000378:metabolism; D011379:Prognosis; D051879:Twist-Related Protein 1 / Q000235:genetics / Q000378:metabolism*
chemical_list: D000071916:AC133 Antigen; D015703:Antigens, CD; D000970:Antineoplastic Agents; D014408:Biomarkers, Tumor; C469949:GNL3 protein, human; D006023:Glycoproteins; D018960:Hyaluronan Receptors; D009687:Nuclear Proteins; C000606023:PROM1 protein, human; D010455:Peptides; C103173:TWIST1 protein, human; D051879:Twist-Related Protein 1; D019204:GTP-Binding Proteins; D002945:Cisplatin; D005472:Fluorouracil